OBJECTIVE: Improved means to monitor and guide interventions could be useful in the intensive care unit. Metabolomic analysis with bioinformatics is used to understand mechanisms and identify biomarkers of disease development and progression. This pilot study evaluated plasma proton nuclear magnetic resonance spectroscopy as a means to monitor metabolism following albumin administration in acute lung injury patients. DESIGN: This study was conducted on plasma samples from six albumin-treated and six saline-treated patients from a larger double-blind trial. The albumin group was administered 25 g of 25% human albumin in 0.9% saline every 8 hrs for a total of nine doses over 72 hrs. A 0.9% concentration of saline was used as a placebo. Blood samples were collected immediately before, 1 hr after, and 4 hrs after the albumin/saline administration for the first, fourth, and seventh doses (first dose of each day for 3 days). Samples were analyzed by proton nuclear magnetic resonance spectroscopy, and spectra were analyzed by principal component analysis and biostatistical methods. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: After 1 day of albumin therapy, changes in small molecules, including amino acids and plasma lipids, were evident with principal component analysis. Differences remained 3 days after the last albumin administration. Analysis of data along with spectra from healthy controls showed that spectra for patients receiving albumin had a trajectory toward the spectra observed for healthy individuals while those of the placebo controls did not. CONCLUSION: The data suggest that metabolic changes detected by proton nuclear magnetic resonance spectroscopy and the bioinformatics tool may be a useful approach to clinical research, especially in acute lung injury.
RCT Entities:
OBJECTIVE: Improved means to monitor and guide interventions could be useful in the intensive care unit. Metabolomic analysis with bioinformatics is used to understand mechanisms and identify biomarkers of disease development and progression. This pilot study evaluated plasma proton nuclear magnetic resonance spectroscopy as a means to monitor metabolism following albumin administration in acute lung injurypatients. DESIGN: This study was conducted on plasma samples from six albumin-treated and six saline-treated patients from a larger double-blind trial. The albumin group was administered 25 g of 25% humanalbumin in 0.9% saline every 8 hrs for a total of nine doses over 72 hrs. A 0.9% concentration of saline was used as a placebo. Blood samples were collected immediately before, 1 hr after, and 4 hrs after the albumin/saline administration for the first, fourth, and seventh doses (first dose of each day for 3 days). Samples were analyzed by proton nuclear magnetic resonance spectroscopy, and spectra were analyzed by principal component analysis and biostatistical methods. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: After 1 day of albumin therapy, changes in small molecules, including amino acids and plasma lipids, were evident with principal component analysis. Differences remained 3 days after the last albumin administration. Analysis of data along with spectra from healthy controls showed that spectra for patients receiving albumin had a trajectory toward the spectra observed for healthy individuals while those of the placebo controls did not. CONCLUSION: The data suggest that metabolic changes detected by proton nuclear magnetic resonance spectroscopy and the bioinformatics tool may be a useful approach to clinical research, especially in acute lung injury.
Authors: Carolyn M Slupsky; Kathryn N Rankin; James Wagner; Hao Fu; David Chang; Aalim M Weljie; Erik J Saude; Bruce Lix; Darryl J Adamko; Sirish Shah; Russ Greiner; Brian D Sykes; Thomas J Marrie Journal: Anal Chem Date: 2007-08-17 Impact factor: 6.986
Authors: Youngja Park; Seoung Bum Kim; Bing Wang; Roberto A Blanco; Ngoc-Anh Le; Shaoxiong Wu; Carolyn J Accardi; R Wayne Alexander; Thomas R Ziegler; Dean P Jones Journal: Am J Physiol Regul Integr Comp Physiol Date: 2009-05-20 Impact factor: 3.619
Authors: Hyun-Woo Cho; Seoung Bum Kim; Myong K Jeong; Youngja Park; Nana Gletsu Miller; Thomas R Ziegler; Dean P Jones Journal: Int J Data Min Bioinform Date: 2008 Impact factor: 0.667
Authors: Pasi Soininen; Antti J Kangas; Peter Würtz; Taru Tukiainen; Tuulia Tynkkynen; Reino Laatikainen; Marjo-Riitta Järvelin; Mika Kähönen; Terho Lehtimäki; Jorma Viikari; Olli T Raitakari; Markku J Savolainen; Mika Ala-Korpela Journal: Analyst Date: 2009-07-30 Impact factor: 4.616
Authors: Roger G Spragg; Gordon R Bernard; William Checkley; J Randall Curtis; Ognjen Gajic; Gordon Guyatt; Jesse Hall; Elliott Israel; Manu Jain; Dale M Needham; Adrienne G Randolph; Gordon D Rubenfeld; David Schoenfeld; B Taylor Thompson; Lorraine B Ware; Duncan Young; Andrea L Harabin Journal: Am J Respir Crit Care Med Date: 2010-03-11 Impact factor: 21.405
Authors: Olaf Beckonert; Hector C Keun; Timothy M D Ebbels; Jacob Bundy; Elaine Holmes; John C Lindon; Jeremy K Nicholson Journal: Nat Protoc Date: 2007 Impact factor: 13.491
Authors: Erik J Saude; Idongesit P Obiefuna; Ray L Somorjai; Farnam Ajamian; Christopher Skappak; Taisir Ahmad; Brion K Dolenko; Brian D Sykes; Redwan Moqbel; Darryl J Adamko Journal: Am J Respir Crit Care Med Date: 2008-10-17 Impact factor: 21.405